PharmEasy Unlisted Shares – Update (2025-2026)
1 – Company Overview
PharmEasy (API Holdings Ltd) is India’s largest online pharmacy and digital healthcare platform, providing drugs, diagnostics, and healthcare services across the country.
2. Latest Financial Update:
In FY25, PharmEasy’s revenue was ₹5,872 crore, slightly up from ₹5,664 crore in FY24.
The company improved financial discipline, reducing losses by 40% to approximately ₹1,516 crore.
Despite progress, the corporation continues to lose money and strives for profitability.
Future Goal:
PharmEasy expects to be profitable by FY27 after restructuring and cost-cutting efforts.
3. Valuation and funding update
Following successive funding rounds, PharmEasy’s valuation fell by over 90% from its peak of $5.6 billion in 2021 to below $700 million.
The company secured approximately $216 million in capital from investors including Manipal Group and previous investors.
4. Debt and Restructuring
PharmEasy has substantial debt obligations, including a $300 million loan from Goldman Sachs with hefty interest rates.
To control finances, the company sold a 10% share in Thyrocare for ₹668 crore, reducing debt strain.
5. Unlisted Share Price (Approximate)
PharmEasy’s unlisted shares on the private market range from ₹5 to ₹7 a share, depending on transaction volume.
Following the value revision, the market capitalization is projected to be between ₹4,000-₹6,000 crore.
Contact Us For More Information
Mail Us : contact@unlistedinvest.com
Contact On : +91 9912004448
Leave a Reply